- Home
- LDP vs AUTL Comparison
LDP vs AUTL Comparison
Compare LDP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDP | AUTL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.9M | 596.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | LDP | AUTL |
|---|---|---|
| Price | $19.38 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.73 |
| AVG Volume (30 Days) | 84.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $98.68 |
| Revenue Next Year | N/A | $28.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $18.83 | $1.18 |
| 52 Week High | $22.05 | $2.58 |
Technical Indicators
Market Signals| Indicator | LDP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 43.44 |
| Support Level | N/A | $1.84 |
| Resistance Level | $20.93 | $1.92 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 43.75 | 34.48 |
Price Performance
Historical ComparisonAbout LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.